Cortex's CEO to Present at Bank of Montreal's Focus on Healthcare Conference on December 6, 2006.IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR) Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Roger G. Stoll, Ph.D., will speak at the Bank of Montreal's Focus on Healthcare Conference taking place December 6 - 7, 2006, at the Millennium Broadway Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Dr. Stoll will give the Company presentation on Tuesday, December 6 at 4:30 PM (EST EST electroshock therapy. EST abbr. electroshock therapy ). The conference will feature a small selected group of companies spanning all sectors of healthcare. Additional information regarding the conference can be found at http:/www.bmocm.com/conferences/healthcare 2006/default.aspx. Dr. Stoll will provide an update on Cortex's AMPAKINE research program, including the progress related to the clinical hold status of its lead low-impact AMPAKINE, CX717 and back-up compounds. He will also discuss new findings on the Company's high-impact AMPAKINE research in Huntington's disease Huntington's disease, hereditary, acute disturbance of the central nervous system usually beginning in middle age and characterized by involuntary muscular movements and progressive intellectual deterioration; formerly called Huntington's chorea. and Fragile X transgenic animal Transgenic animal Animals that have had genes from other species inserted into their genetic code. Mentioned in: Glycogen Storage Diseases models. Also the latest information on the in-licensing program will be discussed. Such products would complement, the activities underway with Cortex's AMPAKINE technology and strengthen the financial support the Company can obtain to develop its own platform technology. The presentation from this conference will be web cast and available for a period of 30 days after the conference by logging on to http://www.bmocm.com/conferences/healthcare2006/webcast/default.aspx. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called Ampakine compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the Ampakine technology. Cortex has alliances with N.V. Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of Ampakine compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) Forward-Looking Statement Note - This press release contains forward-looking statements concerning the Company's research and development activities. The success of such activities depends on a number of factors, including the risks that the Company's proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical test and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. Ampakine compounds are investigational drugs and have not been approved for the treatment of any disease. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion